BASF, Colgate-Palmolive, Estée Lauder, and Unilever Among Keynote Speakers at 2020 Veeva Quality & Regulatory Global Summit
Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Quality & Regulatory Global Summit . Leaders from the world’s top consumer goods, chemical, and cosmetics companies, including BASF, Colgate-Palmolive, Estée Lauder, L’Oréal, Pierre Fabre, Procter & Gamble, Reckitt Benckiser, and Unilever will showcase how they’re modernizing quality management processes and transforming regulatory operations.
The virtual event will take place from October 19-22 and include 20 presentations and panel discussions with more than 30 quality, regulatory, legal, and IT experts from North America and Europe. Visionaries from regulated industries will share strategies and tactics to improve quality, regulatory, and marketing processes across the product lifecycle, including:
- Estée Lauder, Procter & Gamble, and SEQENS discussing strategies they implemented across IT, quality, and regulatory operations to achieve greater resilience and maintain compliance.
- BASF and L’Oréal sharing how they respond to changing market conditions while remaining competitive and compliant across quality, regulatory, and product and process management.
- IFF, L’Occitane, and Procter & Gamble highlighting how consumer demand for safe, sustainable products has brought industries and supply chains closer together to offer better management of advertising claims, compliance, traceability, and circular economies.
“We look forward to hosting a diverse group of industry thought leaders sharing their expertise with their peers across the consumer goods, chemical, and cosmetics industries,” said Frank Defesche, general manager and senior vice president at Veeva. “Attendees will gain new insights to align business and IT priorities and modernize quality management processes, transform regulatory operations, and streamline global management of advertising claims.”
In addition to keynote sessions, participants can choose from 14 sessions in concurrent, customer-led tracks for quality, regulatory, advertising claims management, and IT. Tracks will cover topics such as supporting business continuity, repositioning quality as a strategic growth engine, and implementing strategies to improve supplier collaboration.
The event is complimentary for Veeva customers and quality, regulatory, legal and IT professionals. Learn more, register, and view the full Summit agenda at industries.veeva.com/Summit .
About Veeva for Cosmetics, Consumer Goods, and Chemical Industries
Founded in 2007, Veeva Systems is a global provider of cloud-based software solutions. We help quality, regulatory and commercial teams in the cosmetics, consumer goods, and chemical industries unify disconnected processes, documents and data. In doing so, we help our customers eliminate inefficiencies so they can bring innovative, high-quality products to market faster without compromising compliance. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. Learn more at industries.veeva.com .
For more information about Veeva’s solutions for the global life sciences industry and the more than 875 customers it serves, ranging from the world's largest pharmaceutical companies to emerging biotechs, visit veeva.com/eu .
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARGO-BLOCKCHAIN18.1.2021 09:48:48 CET | Press release
Argo Blockchain PLC announces £22.4 Million Private Placement with Institutional Investors and Mining Capacity Expansion
REPLY18.1.2021 09:32:47 CET | Press release
Reply Signs an Agreement with AWS to Develop Industry Solutions
L&T-TECHNOLOGY-SERVICES18.1.2021 09:02:44 CET | Press release
L&T Technology Services Rated as Global Pure-Play ER&D Services Leader by Zinnov
CA-GUARDANT-HEALTH18.1.2021 09:02:44 CET | Press release
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
NJ-TOPCON-HEALTHCARE18.1.2021 07:02:46 CET | Press release
Topcon Announces eyeRISE 2021 Virtual Symposia & Expo
SERVIER16.1.2021 22:17:39 CET | Press release
Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy
CA-ANDERSEN-GLOBAL15.1.2021 11:01:39 CET | Pressemeddelelse
Andersen Global træder ind i Sverige i samarbejde med Unum Tax
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom